Citigroup Issues Pessimistic Forecast for Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price

Regeneron Pharmaceuticals (NASDAQ:REGN) had its target price reduced by research analysts at Citigroup from $895.00 to $795.00 in a report issued on Tuesday,Benzinga reports. The brokerage presently has a “neutral” rating on the biopharmaceutical company’s stock. Citigroup’s price objective points to a potential upside of 13.02% from the company’s current price.

REGN has been the subject of a number of other reports. JPMorgan Chase & Co. dropped their target price on shares of Regeneron Pharmaceuticals from $1,200.00 to $1,150.00 and set an “overweight” rating for the company in a report on Thursday, October 24th. Royal Bank of Canada cut their price objective on Regeneron Pharmaceuticals from $1,260.00 to $1,215.00 and set an “outperform” rating on the stock in a research report on Friday, November 1st. Cantor Fitzgerald restated a “neutral” rating and set a $1,015.00 target price on shares of Regeneron Pharmaceuticals in a report on Wednesday, October 23rd. Wells Fargo & Company dropped their price target on Regeneron Pharmaceuticals from $1,050.00 to $900.00 and set an “overweight” rating for the company in a research note on Friday, January 10th. Finally, Sanford C. Bernstein reduced their price objective on shares of Regeneron Pharmaceuticals from $1,110.00 to $1,070.00 and set an “outperform” rating on the stock in a research report on Tuesday, January 7th. One analyst has rated the stock with a sell rating, six have assigned a hold rating, sixteen have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, Regeneron Pharmaceuticals currently has a consensus rating of “Moderate Buy” and an average target price of $1,032.57.

Regeneron Pharmaceuticals Stock Up 1.8 %

Shares of NASDAQ REGN opened at $703.43 on Tuesday. The company has a market cap of $77.30 billion, a price-to-earnings ratio of 17.41, a PEG ratio of 1.60 and a beta of 0.10. The company has a quick ratio of 4.46, a current ratio of 5.28 and a debt-to-equity ratio of 0.09. The firm’s fifty day moving average is $746.43 and its 200 day moving average is $956.18. Regeneron Pharmaceuticals has a 52 week low of $666.25 and a 52 week high of $1,211.20.

Hedge Funds Weigh In On Regeneron Pharmaceuticals

A number of hedge funds have recently bought and sold shares of the company. Ashton Thomas Private Wealth LLC bought a new position in shares of Regeneron Pharmaceuticals in the second quarter worth approximately $39,000. Thoroughbred Financial Services LLC bought a new position in Regeneron Pharmaceuticals in the 2nd quarter valued at approximately $515,000. Envestnet Asset Management Inc. lifted its position in Regeneron Pharmaceuticals by 12.2% in the 2nd quarter. Envestnet Asset Management Inc. now owns 75,452 shares of the biopharmaceutical company’s stock valued at $79,303,000 after acquiring an additional 8,209 shares in the last quarter. Massachusetts Financial Services Co. MA boosted its stake in Regeneron Pharmaceuticals by 12.4% during the 2nd quarter. Massachusetts Financial Services Co. MA now owns 540,293 shares of the biopharmaceutical company’s stock valued at $567,864,000 after purchasing an additional 59,769 shares during the last quarter. Finally, Lmcg Investments LLC increased its holdings in shares of Regeneron Pharmaceuticals by 4.7% in the 2nd quarter. Lmcg Investments LLC now owns 4,832 shares of the biopharmaceutical company’s stock worth $5,079,000 after purchasing an additional 215 shares in the last quarter. Institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Company Profile

Regeneron Pharmaceuticals, Inc discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity.